Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction
Abstract Elevation of total cell-free DNA (cfDNA) in patients with preeclampsia is well-known; however, whether this change precedes the onset of symptoms remains inconclusive. Here, we conducted a nested case–control study to determine the elevation of cfDNA levels in women who subsequently develop...
Guardado en:
Autores principales: | , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c8dd70c1ea094b8a98d6e721f0060274 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:c8dd70c1ea094b8a98d6e721f0060274 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:c8dd70c1ea094b8a98d6e721f00602742021-12-02T15:32:59ZMaternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction10.1038/s41598-020-68842-12045-2322https://doaj.org/article/c8dd70c1ea094b8a98d6e721f00602742020-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-68842-1https://doaj.org/toc/2045-2322Abstract Elevation of total cell-free DNA (cfDNA) in patients with preeclampsia is well-known; however, whether this change precedes the onset of symptoms remains inconclusive. Here, we conducted a nested case–control study to determine the elevation of cfDNA levels in women who subsequently developed preeclampsia. Methylated HYP2 (m-HYP2) levels were determined in 68 blood samples collected from women with hypertensive disorders of pregnancy, along with 136 control samples, using real-time quantitative PCR. The measured m-HYP2 levels were converted to multiples of the median (MoM) values for correction of maternal characteristics. The m-HYP2 levels and MoM values in patients with preeclampsia were significantly higher than in controls during the third trimester (P < 0.001, both), whereas those for women who subsequently developed preeclampsia did not differ during the second trimester. However, when patients with preeclampsia were divided based on the onset-time of preeclampsia or 10th percentile birth weight, both values were significantly higher in women who subsequently developed early-onset preeclampsia (P < 0.05, both) and preeclampsia with small-for-gestational-age (SGA) neonate (P < 0.01, both) than controls. These results suggested that total cfDNA levels could be used to predict early-onset preeclampsia or preeclampsia with SGA neonate.Dong Wook KwakShin Young KimHyun Jin KimJi Hyae LimYoung-Han KimHyun Mee RyuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-8 (2020) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Dong Wook Kwak Shin Young Kim Hyun Jin Kim Ji Hyae Lim Young-Han Kim Hyun Mee Ryu Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction |
description |
Abstract Elevation of total cell-free DNA (cfDNA) in patients with preeclampsia is well-known; however, whether this change precedes the onset of symptoms remains inconclusive. Here, we conducted a nested case–control study to determine the elevation of cfDNA levels in women who subsequently developed preeclampsia. Methylated HYP2 (m-HYP2) levels were determined in 68 blood samples collected from women with hypertensive disorders of pregnancy, along with 136 control samples, using real-time quantitative PCR. The measured m-HYP2 levels were converted to multiples of the median (MoM) values for correction of maternal characteristics. The m-HYP2 levels and MoM values in patients with preeclampsia were significantly higher than in controls during the third trimester (P < 0.001, both), whereas those for women who subsequently developed preeclampsia did not differ during the second trimester. However, when patients with preeclampsia were divided based on the onset-time of preeclampsia or 10th percentile birth weight, both values were significantly higher in women who subsequently developed early-onset preeclampsia (P < 0.05, both) and preeclampsia with small-for-gestational-age (SGA) neonate (P < 0.01, both) than controls. These results suggested that total cfDNA levels could be used to predict early-onset preeclampsia or preeclampsia with SGA neonate. |
format |
article |
author |
Dong Wook Kwak Shin Young Kim Hyun Jin Kim Ji Hyae Lim Young-Han Kim Hyun Mee Ryu |
author_facet |
Dong Wook Kwak Shin Young Kim Hyun Jin Kim Ji Hyae Lim Young-Han Kim Hyun Mee Ryu |
author_sort |
Dong Wook Kwak |
title |
Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction |
title_short |
Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction |
title_full |
Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction |
title_fullStr |
Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction |
title_full_unstemmed |
Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction |
title_sort |
maternal total cell-free dna in preeclampsia with and without intrauterine growth restriction |
publisher |
Nature Portfolio |
publishDate |
2020 |
url |
https://doaj.org/article/c8dd70c1ea094b8a98d6e721f0060274 |
work_keys_str_mv |
AT dongwookkwak maternaltotalcellfreednainpreeclampsiawithandwithoutintrauterinegrowthrestriction AT shinyoungkim maternaltotalcellfreednainpreeclampsiawithandwithoutintrauterinegrowthrestriction AT hyunjinkim maternaltotalcellfreednainpreeclampsiawithandwithoutintrauterinegrowthrestriction AT jihyaelim maternaltotalcellfreednainpreeclampsiawithandwithoutintrauterinegrowthrestriction AT younghankim maternaltotalcellfreednainpreeclampsiawithandwithoutintrauterinegrowthrestriction AT hyunmeeryu maternaltotalcellfreednainpreeclampsiawithandwithoutintrauterinegrowthrestriction |
_version_ |
1718387168917848064 |